A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBiotheus Inc.
About this trial
This study to evaluate the preliminary efficacy, safety and pharmacokinetics of PM8002 combined with PM1009 in Patients with first-line Hepatocellular Carcinoma.
Eligibility criteria
Qualifiers
Voluntary participation in clinical studies;
Male or female, aged ≥ 18 years;
Pathologically or clinically confirmed (according to AASLD), unresectable locally advanced and/or metastatic HCC;
Child-Pugh liver function score ≤7；
Disqualifiers
Pathologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma and other components；
History of serious allergic diseases；
The toxicity of previous anti-tumor therapy has not been alleviated；
History of severe cardiovascular diseases within 6 months;
Trial design
Treatments tested in this trial
- PM8002
- PM1009
- atezolizumab
- bevacizumab
Treatment groups
140 Participants
are divided into 4 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov